While combined chemotherapy regimens can be effective in classical Hodgkin's lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL), around a third of patients are unresponsive or relapse within a few years of treatment. Allogeneic stem cell transplantation (allo-SCT) may achieve long-term disease control in patients with chemoresistant disease, but many patients are unable to undergo allo-SCT.
Professor of Hematology
Chemotherapy achieves excellent response rates and long progressionfree survival (PFS) in classical Hodgkin's lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL). 1 However, up to 30 % of patients with advanced HL do not achieve remission or relapse within a few years of initial treatment. 2 Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (HD+ASCT) is the standard of care for patients with chemosensitive refractory or relapsed cHL. 1 However, the prognosis is poor for patients who relapse following HD+ASCT. 3 Independent risk factors for overall survival (OS) include early relapse (<6 months) after ASCT, stage IV, bulky disease, poor performance status (PS) and age ≥50 years at relapse. 4 For patients with sALCL, the benefits of SCT are less clear, and patients not achieving a complete response (CR) or at least a good partial response (PR) before HD+ASCT usually have a poor prognosis.
Moreover, patients that relapse after HD+ASCT have few effective treatment options.
In patients with chemo-refractory disease who are otherwise clinically fit, allogeneic stem cell transplantation (allo-SCT) has been shown to have a curative potential as a result of the underlying graft-versuslymphoma (GvL) effect. However, many patients are unable to undergo allo-SCT, and treatment with brentuximab vedotin (BV) provides an alternative for these patients. On the basis of a number of pivotal clinical trial data, [5] [6] [7] [8] BV was granted accelerated approval by the US Food and Drug Administration (FDA) and conditional approval by the European Medicines Agency (EMA) for the treatment of patients with cHL after failure of auto-SCT or after failure of at least two prior chemotherapy regimens in patients who are not auto-SCT candidates, and for the treatment of patients with sALCL after failure of at least one prior combined chemotherapy regimen. This article aims, through a series of case studies, to demonstrate the use of BV in selected patient groups with relapsed/refractory cHL and sALCL.
The Use of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin's Lymphoma and Systemic Anaplastic Large Cell Lymphoma
The role of allo-SCT in cHL is not well established and is considered controversial. [9] [10] [11] [12] [13] The treatment is associated with significant toxicity and results in few long-term disease-free survivors. Reduced-intensity conditioning (RIC) has lowered the treatment-related mortality; however, it confers an increased risk of early relapse, with disease relapse and progression reported in more than half of patients. [14] [15] [16] In addition, there are limited treatment options for patients who relapse after allo-SCT, in part due to the challenge of giving systemic antineoplastic therapy to the graft bone marrow cells. 17 An expert panel has recommended that allo-SCT may be used in a tandem strategy after HD+ASCT, provided the patient is sensitive to salvage chemotherapy and does not display disease progression between the two transplants. allo-SCT may also be considered in patients relapsing after an ASCT, provided the patient is sensitive to salvage chemotherapy. 10, 18 Factors that Prevent Patients from Proceeding to Stem Cell Transplantation A significant proportion of patients are not eligible for SCT, including those who do not either achieve sufficient clinical response to proceed to transplantation, or harbour a chemosensitive disease. In addition, elderly patients, or those with comorbidities, may be unable to tolerate intensive therapy.
There are three distinct patient subgroups for which BV may be particularly beneficial:
• Patients with cHL who relapse after HD+ASCT and therefore are potential candidates for allo-SCT. Only relatively young (<70), fit patients are eligible for the latter.
• Patients with cHL who have had an unsatisfactory response to at least two prior treatments and are not eligible for SCT.
• Any patient with sALCL who has failed the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisolone).
Brentuximab Vedotin as a Bridge to Stem Cell Transplantation in Clinical Studies
Several studies have investigated the use of BV as a bridge to transplantation in patients who might not otherwise fulfil the criteria for allo-SCT. A retrospective study of 14 patients with refractory or relapsed cHL who had not received prior HD+ASCT due to refractory disease (n=9), comorbidity (n=4) and unknown reason (n=1), found that BV resulted in an overall response rate (ORR) of 71 % with CR in 36 %, and allowed consolidating HD+ASCT to be performed in four patients and allo-SCT in one patient. 19 BV has also been investigated as a means of reducing tumour burden to facilitate consolidative allo-SCT, improving post-transplantation disease-free survival. Fifteen patients who participated in the pivotal phase II studies of BV received consolidative allo-SCT following BV treatment. The 2-year PFS of these patients was estimated to be 66 % and the median PFS had not yet been reached at the time of reporting. Eleven patients were alive and the estimated 2-year OS rate was 80 %. 20 In a retrospective analysis, the outcomes of 23 cHL patients who underwent RIC allo-SCT with no prior BV exposure were compared with those of 21 additional cHL patients who had received BV prior to RIC allo-SCT. The patients who received BV prior to RIC allo-SCT showed better haematopoietic cell transplantation comorbidity index (HCT-CI), better remission status at time of transplant and reduced peri-transplant toxicity. 21 In another study of patients who underwent allo-SCT (n=27), 52 % received BV prior to allo-SCT, and in seven patients, it was the last therapy prior to allo-SCT. In these seven patients the CR rate was 100 %, indicating that a BV-based transplant strategy is useful in this high-risk patient group. 22 
Brentuximab Vedotin as a Bridge to Stem Cell Transplantation in Real Life Clinical Practice
In order for BV to be used as an alternative to allo-SCT in clinical practice, several practical considerations must be addressed. The optimal timing of allo-SCT after BV response in this setting remains a challenge. In addition, it is not known who would benefit from allo-SCT soon after reaching remission versus sustained treatment with BV. In an Italian study (n=65), best ORR were obtained after three to four cycles. 23 A recent Turkish study (n=58), found that BV provided a bridge to transplantation in approximately one-quarter of the patients. However, responses were not always sustained during the course of treatment suggesting that transplantation should be implemented early during treatment and not as late as after up to 16 treatment cycles. Symptoms improved gradually with neurological habilitation over several months. In April 2014, the patient was in complete remission from ALCL
